1. Home
  2. PKOH vs ALLO Comparison

PKOH vs ALLO Comparison

Compare PKOH & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park-Ohio Holdings Corp.

PKOH

Park-Ohio Holdings Corp.

HOLD

Current Price

$25.34

Market Cap

299.5M

Sector

Industrials

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.29

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PKOH
ALLO
Founded
1907
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
299.5M
252.9M
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
PKOH
ALLO
Price
$25.34
$2.29
Analyst Decision
Buy
Strong Buy
Analyst Count
1
12
Target Price
$37.00
$8.27
AVG Volume (30 Days)
23.2K
4.6M
Earning Date
06-11-2026
01-01-0001
Dividend Yield
1.80%
N/A
EPS Growth
N/A
36.84
EPS
1.70
N/A
Revenue
$1,599,100,000.00
$22,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.72
N/A
P/E Ratio
$17.61
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.52
$0.86
52 Week High
$29.50
$2.80

Technical Indicators

Market Signals
Indicator
PKOH
ALLO
Relative Strength Index (RSI) 48.85 55.27
Support Level $19.01 $1.01
Resistance Level $28.50 $2.80
Average True Range (ATR) 1.32 0.20
MACD -0.22 -0.01
Stochastic Oscillator 7.06 49.01

Price Performance

Historical Comparison
PKOH
ALLO

About PKOH Park-Ohio Holdings Corp.

Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: